Axogen inc
Officers & Directors
John H. Johnson - Adam M. Levine - Karen Zaderej - Chief Executive Officer, President and Chairman of the Board - Joseph A. Tyndall - Guido J. Neels - Amy Wendell - Kathy Weiler - Director Nir Naor - William P. Burke - Gregory G. Freitag - ,
Axogen inc currently has 622 employees.
News about Axogen inc Key Personnel |
IntroductionAxogen Inc. a prominent player in surgical solutions for peripheral nerve injuries, has made significant strides despite facing various challenges. The recent appointment of Craig Swandal, an experienced executive in medical device manufacturing, as the new Vice President of Operations marks a strategic move for the company s leadership team. Coupled with a reported revenue increase and employee growth metrics, these developments reflect Axogen s strategic initiatives to enhance its business while grappling with financial setbacks.Fact 1: New Leadership and Inducement GrantOn July 1, 2024, Axogen announced an inducement grant under NASDAQ listing rule 5635(c)(4) to attract a new non-executive emp...
|
Axogen Inc, a global leader in surgical solutions for peripheral nerve injuries, recently reported an inducement grant made under NASDAQ listing rule 5635(c)(4) in connection with the hiring of a new non-executive employee. This news comes at a time when the company recorded a cumulative net loss of $24 million and experienced a decline in its return on assets within the healthcare sector. In this article, we will outline the facts surrounding these events and assess their impact on Axogen Inc.
Fact 1: Inducement Grant for New Non-Executive Employee
On July 1, 2024, Axogen Inc announced an inducement grant made under NASDAQ listing rule 5635(c)(4) for a new non-executive employee. This gran...
|
Alachua, Fla. and Tampa, Fla., May 16, 2024 - Axogen Inc. (NASDAQ: AXGN), a recognized global leader in the development and marketing of innovative surgical solutions for peripheral nerve injuries, is proud to announce the commencement of the rolling submission process for a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for licensure of Avance Nerve Graft. This significant milestone was achieved on May 15, 2024.
Avance Nerve Graft, Axogen s pioneering surgical solution, has demonstrated immense potential in addressing peripheral nerve injuries. With the initiation of the BLA submission process, Axogen is taking a crucial step towards making this revolution...
|
Axogen Announces Leadership Transition as CEO Karen Zaderej Retires from Company in January 2025
ALACHUA and TAMPA, Fla., Jan. 4, 2024 - Axogen, Inc. (NASDAQ: AXGN), a pioneering force in developing and marketing groundbreaking surgical solutions for peripheral nerve injuries, has revealed its plan for a leadership transition, with President and CEO Karen Zaderej expected to retire from the company by January 2025. This strategic decision marks a significant turning point in Axogen s journey, as it paves the way for a new leader to guide the company towards continued innovation and growth.
The organization s Board of Directors has taken a proactive approach to ensure a smooth transition by initiating...
|
Axogen, Inc. Announces Inducement Grants for New VP of Finance and Investor Relations Amidst Cumulative Net Loss
In a recent announcement, Axogen, Inc. (NASDAQ: AXGN), a renowned global player in the field of innovative surgical solutions for peripheral nerve injuries, revealed their decision to make Inducement Grants under NASDAQ Listing Rule 5635(c)(4). These grants are in connection with the appointment of Harold D. Tamayo as the Vice President of Finance and Investor Relations. This move is aimed at fortifying Axogen s financial capabilities and optimizing investor relations. Mr. Tamayo, who will report to Peter J. Mariani, the Executive Vice President and Chief Financial Officer, will be entrus...
|
|
|
